• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 1
  3. Author

Online ISSN: 2515-8260

Volume9, Issue1

Association between second trimester maternal serum alphafetoprotein in 14-22 weeks and adverse pregnancy outcome

    Heena Mir, Saima Sadiq,Sabha Malik

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 1, Pages 225-230

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background:Many screening tests are available for predicting adverse pregnancy outcome
and these range from non- invasive to invasive and serum alpha-fetoprotein level
estimation is one of them. The present study was conducted to assess association between
second trimester maternal serum alpha-fetoprotein in 14-22 weeks and adverse pregnancy
outcome.
Materials & Methods: 250 patients of gestational age between 14-22 weeks were included.
Maternal serum alpha-fetoprotein was measured in human serum by microplateimmunoenzymometric
assay by EIA-AFP kit. Maternal serum alpha-feto protein level was
expressed in IU/ml.
Results: 23 (9.2%) participants out of 250 developed preterm labor. 21 out of 23 had raised
value of maternal serum alpha-fetoprotein. 20 (8%) patients out of 250 patients developed
oligohydramnios. 13 out of 20 had raised value of maternal serum alpha-fetoprotein. 14
(5.6%) patients out of 250 developed pre-eclampsia, 11 out of 14 had raised values of
maternal serum alpha-fetoprotein. 7 (2.8%) patients out of 250 developed premature
rupture of membrane (PROM). 4 out of 7 had raised values of maternal serum alphafetoprotein.
Conclusion: There is an increased risk of pre-eclampsia, preterm delivery,
oligohydramnios and premature rupture of membrane with elevated maternal serum
alpha-fetoprotein levels
Keywords:
    Pre-eclampsia preterm delivery Oligohydramnios
  • PDF (387 K)
  • XML
(2022). Association between second trimester maternal serum alphafetoprotein in 14-22 weeks and adverse pregnancy outcome. European Journal of Molecular & Clinical Medicine, 9(1), 225-230.
Heena Mir, Saima Sadiq,Sabha Malik. "Association between second trimester maternal serum alphafetoprotein in 14-22 weeks and adverse pregnancy outcome". European Journal of Molecular & Clinical Medicine, 9, 1, 2022, 225-230.
(2022). 'Association between second trimester maternal serum alphafetoprotein in 14-22 weeks and adverse pregnancy outcome', European Journal of Molecular & Clinical Medicine, 9(1), pp. 225-230.
Association between second trimester maternal serum alphafetoprotein in 14-22 weeks and adverse pregnancy outcome. European Journal of Molecular & Clinical Medicine, 2022; 9(1): 225-230.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 180
  • PDF Download: 166
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus